A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
29actual
Sites
15
Countries
Bulgaria, Hungary, Romania +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-09 | actual | When the study began enrolling |
| Primary completion | 2025-10-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-27 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Kidney Disease
- Atherosclerotic Cardiovascular Disease
Interventions
- Drug: AZD4144
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events
measured From first dose (Day 1) until Follow-up (Day 56±1)
Relative change from baseline to 4 weeks in systemic Interleukin-6 (IL-6) levels
measured Day 1 to Day 28
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed